nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Docetaxel—skin cancer	0.506	0.685	CbGbCtD
Rasagiline—CYP1A2—Imiquimod—skin cancer	0.105	0.142	CbGbCtD
Rasagiline—CYP1A2—Vemurafenib—skin cancer	0.0577	0.078	CbGbCtD
Rasagiline—CYP1A2—Dacarbazine—skin cancer	0.0442	0.0598	CbGbCtD
Rasagiline—CYP1A2—Fluorouracil—skin cancer	0.0259	0.0351	CbGbCtD
Rasagiline—MAOB—Dopamine metabolism—TYR—skin cancer	0.013	0.309	CbGpPWpGaD
Rasagiline—BCL2—neck—skin cancer	0.00385	0.137	CbGeAlD
Rasagiline—MAOB—nerve—skin cancer	0.00286	0.101	CbGeAlD
Rasagiline—BCL2—connective tissue—skin cancer	0.00276	0.0981	CbGeAlD
Rasagiline—BCL2—epithelium—skin cancer	0.00262	0.0931	CbGeAlD
Rasagiline—BCL2—skin of body—skin cancer	0.00249	0.0886	CbGeAlD
Rasagiline—BCL2—lymphoid tissue—skin cancer	0.00202	0.0717	CbGeAlD
Rasagiline—BCL2—female reproductive system—skin cancer	0.00195	0.0692	CbGeAlD
Rasagiline—BCL2—head—skin cancer	0.00163	0.0578	CbGeAlD
Rasagiline—MAOB—nipple—skin cancer	0.00162	0.0576	CbGeAlD
Rasagiline—BCL2—Corticotropin-releasing hormone—KRT14—skin cancer	0.00151	0.0361	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MSH2—skin cancer	0.0015	0.0356	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—MITF—skin cancer	0.00139	0.0332	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—MITF—skin cancer	0.00124	0.0295	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—RASA1—skin cancer	0.00119	0.0283	CbGpPWpGaD
Rasagiline—CYP1A2—nipple—skin cancer	0.00115	0.041	CbGeAlD
Rasagiline—MAOB—connective tissue—skin cancer	0.00115	0.0408	CbGeAlD
Rasagiline—BCL2—lymph node—skin cancer	0.00114	0.0405	CbGeAlD
Rasagiline—BCL2—TP53 Network—CDKN2A—skin cancer	0.00103	0.0244	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—BRAF—skin cancer	0.00102	0.0243	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—PTGS2—skin cancer	0.000958	0.0228	CbGpPWpGaD
Rasagiline—MAOB—mammalian vulva—skin cancer	0.000947	0.0336	CbGeAlD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—TERT—skin cancer	0.000879	0.021	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000865	0.0206	CbGpPWpGaD
Rasagiline—MAOB—female reproductive system—skin cancer	0.000811	0.0288	CbGeAlD
Rasagiline—BCL2—Integrated Cancer Pathway—CDK4—skin cancer	0.000685	0.0163	CbGpPWpGaD
Rasagiline—MAOB—head—skin cancer	0.000677	0.0241	CbGeAlD
Rasagiline—BCL2—Direct p53 effectors—MSH2—skin cancer	0.000592	0.0141	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—skin cancer	0.00057	0.0136	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000558	0.0133	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CDK4—skin cancer	0.000542	0.0129	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MLH1—skin cancer	0.000534	0.0127	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—IL6—skin cancer	0.000522	0.0124	CbGpPWpGaD
Rasagiline—MAOB—lymph node—skin cancer	0.000474	0.0168	CbGeAlD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—skin cancer	0.000458	0.0109	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000434	0.0104	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000412	0.00982	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—HRAS—skin cancer	0.00036	0.00857	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—KRAS—skin cancer	0.000354	0.00844	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—BRAF—skin cancer	0.000336	0.00801	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—skin cancer	0.000328	0.00781	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—skin cancer	0.000328	0.00781	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—skin cancer	0.000323	0.00771	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—skin cancer	0.000312	0.00744	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDKN2A—skin cancer	0.000312	0.00744	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—BRAF—skin cancer	0.000302	0.00721	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—skin cancer	0.000293	0.00698	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—skin cancer	0.000292	0.00696	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—skin cancer	0.000291	0.00695	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—skin cancer	0.000289	0.0069	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TLR7—skin cancer	0.000284	0.00677	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—skin cancer	0.000279	0.00664	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—skin cancer	0.000278	0.00663	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	0.000261	0.00622	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—skin cancer	0.000256	0.0061	CbGpPWpGaD
Rasagiline—Stomatitis—Fluorouracil—skin cancer	0.000256	0.00134	CcSEcCtD
Rasagiline—Haemorrhage—Temozolomide—skin cancer	0.000256	0.00134	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000255	0.00609	CbGpPWpGaD
Rasagiline—Conjunctivitis—Fluorouracil—skin cancer	0.000255	0.00133	CcSEcCtD
Rasagiline—Asthenia—Vemurafenib—skin cancer	0.000255	0.00133	CcSEcCtD
Rasagiline—Hallucination—Temozolomide—skin cancer	0.000254	0.00133	CcSEcCtD
Rasagiline—Hypoaesthesia—Temozolomide—skin cancer	0.000254	0.00133	CcSEcCtD
Rasagiline—Chills—Dactinomycin—skin cancer	0.000253	0.00133	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—skin cancer	0.000253	0.00604	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Temozolomide—skin cancer	0.000252	0.00132	CcSEcCtD
Rasagiline—Oedema peripheral—Temozolomide—skin cancer	0.000252	0.00132	CcSEcCtD
Rasagiline—Cardiac failure—Docetaxel—skin cancer	0.000252	0.00132	CcSEcCtD
Rasagiline—Pruritus—Vemurafenib—skin cancer	0.000251	0.00131	CcSEcCtD
Rasagiline—Connective tissue disorder—Temozolomide—skin cancer	0.000251	0.00131	CcSEcCtD
Rasagiline—Urethral disorder—Temozolomide—skin cancer	0.00025	0.00131	CcSEcCtD
Rasagiline—Alopecia—Dactinomycin—skin cancer	0.00025	0.00131	CcSEcCtD
Rasagiline—Feeling abnormal—Imiquimod—skin cancer	0.00025	0.00131	CcSEcCtD
Rasagiline—Gastrointestinal pain—Imiquimod—skin cancer	0.000248	0.0013	CcSEcCtD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—skin cancer	0.000248	0.0059	CbGpPWpGaD
Rasagiline—Epistaxis—Fluorouracil—skin cancer	0.000247	0.00129	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000246	0.00129	CcSEcCtD
Rasagiline—Ill-defined disorder—Bleomycin—skin cancer	0.000245	0.00128	CcSEcCtD
Rasagiline—Anaemia—Bleomycin—skin cancer	0.000244	0.00128	CcSEcCtD
Rasagiline—Diarrhoea—Vemurafenib—skin cancer	0.000243	0.00127	CcSEcCtD
Rasagiline—Migraine—Docetaxel—skin cancer	0.000242	0.00127	CcSEcCtD
Rasagiline—Urticaria—Imiquimod—skin cancer	0.000241	0.00126	CcSEcCtD
Rasagiline—Abdominal pain—Imiquimod—skin cancer	0.000239	0.00125	CcSEcCtD
Rasagiline—Body temperature increased—Imiquimod—skin cancer	0.000239	0.00125	CcSEcCtD
Rasagiline—Eye disorder—Temozolomide—skin cancer	0.000239	0.00125	CcSEcCtD
Rasagiline—Malaise—Bleomycin—skin cancer	0.000238	0.00124	CcSEcCtD
Rasagiline—Cardiac disorder—Temozolomide—skin cancer	0.000237	0.00124	CcSEcCtD
Rasagiline—Haemoglobin—Fluorouracil—skin cancer	0.000237	0.00124	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—skin cancer	0.000237	0.00564	CbGpPWpGaD
Rasagiline—Leukopenia—Bleomycin—skin cancer	0.000236	0.00124	CcSEcCtD
Rasagiline—Rhinitis—Fluorouracil—skin cancer	0.000236	0.00123	CcSEcCtD
Rasagiline—Haemorrhage—Fluorouracil—skin cancer	0.000235	0.00123	CcSEcCtD
Rasagiline—Dizziness—Vemurafenib—skin cancer	0.000235	0.00123	CcSEcCtD
Rasagiline—Hypoaesthesia—Fluorouracil—skin cancer	0.000234	0.00123	CcSEcCtD
Rasagiline—Angiopathy—Temozolomide—skin cancer	0.000232	0.00121	CcSEcCtD
Rasagiline—Ataxia—Docetaxel—skin cancer	0.000231	0.00121	CcSEcCtD
Rasagiline—Immune system disorder—Temozolomide—skin cancer	0.000231	0.00121	CcSEcCtD
Rasagiline—Mediastinal disorder—Temozolomide—skin cancer	0.00023	0.0012	CcSEcCtD
Rasagiline—Cough—Bleomycin—skin cancer	0.00023	0.0012	CcSEcCtD
Rasagiline—Chills—Temozolomide—skin cancer	0.000229	0.0012	CcSEcCtD
Rasagiline—Ill-defined disorder—Dactinomycin—skin cancer	0.000228	0.00119	CcSEcCtD
Rasagiline—Anaemia—Dactinomycin—skin cancer	0.000227	0.00119	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—skin cancer	0.000227	0.00541	CbGpPWpGaD
Rasagiline—Liver function test abnormal—Docetaxel—skin cancer	0.000227	0.00119	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000226	0.00539	CbGpPWpGaD
Rasagiline—Vomiting—Vemurafenib—skin cancer	0.000226	0.00118	CcSEcCtD
Rasagiline—Alopecia—Temozolomide—skin cancer	0.000226	0.00118	CcSEcCtD
Rasagiline—Chest pain—Bleomycin—skin cancer	0.000224	0.00117	CcSEcCtD
Rasagiline—Orthostatic hypotension—Docetaxel—skin cancer	0.000224	0.00117	CcSEcCtD
Rasagiline—Rash—Vemurafenib—skin cancer	0.000224	0.00117	CcSEcCtD
Rasagiline—Mental disorder—Temozolomide—skin cancer	0.000224	0.00117	CcSEcCtD
Rasagiline—Dermatitis—Vemurafenib—skin cancer	0.000224	0.00117	CcSEcCtD
Rasagiline—Hypersensitivity—Imiquimod—skin cancer	0.000223	0.00117	CcSEcCtD
Rasagiline—Headache—Vemurafenib—skin cancer	0.000223	0.00116	CcSEcCtD
Rasagiline—Malnutrition—Temozolomide—skin cancer	0.000222	0.00116	CcSEcCtD
Rasagiline—Discomfort—Bleomycin—skin cancer	0.000222	0.00116	CcSEcCtD
Rasagiline—Malaise—Dactinomycin—skin cancer	0.000222	0.00116	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—skin cancer	0.00022	0.00525	CbGpPWpGaD
Rasagiline—Leukopenia—Dactinomycin—skin cancer	0.00022	0.00115	CcSEcCtD
Rasagiline—Dysgeusia—Temozolomide—skin cancer	0.000218	0.00114	CcSEcCtD
Rasagiline—Asthenia—Imiquimod—skin cancer	0.000217	0.00114	CcSEcCtD
Rasagiline—Confusional state—Bleomycin—skin cancer	0.000217	0.00114	CcSEcCtD
Rasagiline—Back pain—Temozolomide—skin cancer	0.000215	0.00113	CcSEcCtD
Rasagiline—Pruritus—Imiquimod—skin cancer	0.000214	0.00112	CcSEcCtD
Rasagiline—Infection—Bleomycin—skin cancer	0.000214	0.00112	CcSEcCtD
Rasagiline—Dysphagia—Docetaxel—skin cancer	0.000212	0.00111	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000212	0.00505	CbGpPWpGaD
Rasagiline—Nausea—Vemurafenib—skin cancer	0.000211	0.0011	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—skin cancer	0.000211	0.00503	CbGpPWpGaD
Rasagiline—Tremor—Temozolomide—skin cancer	0.000208	0.00109	CcSEcCtD
Rasagiline—Alopecia—Fluorouracil—skin cancer	0.000208	0.00109	CcSEcCtD
Rasagiline—Diarrhoea—Imiquimod—skin cancer	0.000207	0.00108	CcSEcCtD
Rasagiline—Discomfort—Dactinomycin—skin cancer	0.000207	0.00108	CcSEcCtD
Rasagiline—Angina pectoris—Docetaxel—skin cancer	0.000207	0.00108	CcSEcCtD
Rasagiline—Ill-defined disorder—Temozolomide—skin cancer	0.000206	0.00108	CcSEcCtD
Rasagiline—Anaemia—Temozolomide—skin cancer	0.000206	0.00108	CcSEcCtD
Rasagiline—Anorexia—Bleomycin—skin cancer	0.000205	0.00107	CcSEcCtD
Rasagiline—Agitation—Temozolomide—skin cancer	0.000204	0.00107	CcSEcCtD
Rasagiline—Hypotension—Bleomycin—skin cancer	0.000201	0.00105	CcSEcCtD
Rasagiline—Malaise—Temozolomide—skin cancer	0.000201	0.00105	CcSEcCtD
Rasagiline—Dizziness—Imiquimod—skin cancer	0.0002	0.00105	CcSEcCtD
Rasagiline—Vertigo—Temozolomide—skin cancer	0.0002	0.00105	CcSEcCtD
Rasagiline—Infection—Dactinomycin—skin cancer	0.000199	0.00104	CcSEcCtD
Rasagiline—Leukopenia—Temozolomide—skin cancer	0.000199	0.00104	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000196	0.00103	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—skin cancer	0.000195	0.00466	CbGpPWpGaD
Rasagiline—Cough—Temozolomide—skin cancer	0.000194	0.00102	CcSEcCtD
Rasagiline—Paraesthesia—Bleomycin—skin cancer	0.000193	0.00101	CcSEcCtD
Rasagiline—Convulsion—Temozolomide—skin cancer	0.000193	0.00101	CcSEcCtD
Rasagiline—Vomiting—Imiquimod—skin cancer	0.000193	0.00101	CcSEcCtD
Rasagiline—Weight decreased—Docetaxel—skin cancer	0.000192	0.001	CcSEcCtD
Rasagiline—Hypertension—Temozolomide—skin cancer	0.000192	0.001	CcSEcCtD
Rasagiline—Dyspnoea—Bleomycin—skin cancer	0.000192	0.001	CcSEcCtD
Rasagiline—Anorexia—Dactinomycin—skin cancer	0.000191	0.001	CcSEcCtD
Rasagiline—Rash—Imiquimod—skin cancer	0.000191	0.000999	CcSEcCtD
Rasagiline—Dermatitis—Imiquimod—skin cancer	0.000191	0.000998	CcSEcCtD
Rasagiline—Headache—Imiquimod—skin cancer	0.00019	0.000993	CcSEcCtD
Rasagiline—Anaemia—Fluorouracil—skin cancer	0.000189	0.000991	CcSEcCtD
Rasagiline—Arthralgia—Temozolomide—skin cancer	0.000189	0.000991	CcSEcCtD
Rasagiline—Infestation—Docetaxel—skin cancer	0.000189	0.00099	CcSEcCtD
Rasagiline—Infestation NOS—Docetaxel—skin cancer	0.000189	0.00099	CcSEcCtD
Rasagiline—Anxiety—Temozolomide—skin cancer	0.000189	0.000987	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—BRAF—skin cancer	0.000188	0.00448	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000188	0.000984	CcSEcCtD
Rasagiline—Discomfort—Temozolomide—skin cancer	0.000187	0.000979	CcSEcCtD
Rasagiline—Decreased appetite—Bleomycin—skin cancer	0.000187	0.000979	CcSEcCtD
Rasagiline—Acute coronary syndrome—Docetaxel—skin cancer	0.000187	0.000976	CcSEcCtD
Rasagiline—Neuropathy peripheral—Docetaxel—skin cancer	0.000186	0.000971	CcSEcCtD
Rasagiline—Myocardial infarction—Docetaxel—skin cancer	0.000186	0.000971	CcSEcCtD
Rasagiline—Dry mouth—Temozolomide—skin cancer	0.000185	0.000969	CcSEcCtD
Rasagiline—Stomatitis—Docetaxel—skin cancer	0.000184	0.000965	CcSEcCtD
Rasagiline—Jaundice—Docetaxel—skin cancer	0.000184	0.000965	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—skin cancer	0.000184	0.00439	CbGpPWpGaD
Rasagiline—Conjunctivitis—Docetaxel—skin cancer	0.000184	0.000963	CcSEcCtD
Rasagiline—Leukopenia—Fluorouracil—skin cancer	0.000183	0.00096	CcSEcCtD
Rasagiline—Confusional state—Temozolomide—skin cancer	0.000183	0.000958	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000183	0.000957	CcSEcCtD
Rasagiline—Infection—Temozolomide—skin cancer	0.00018	0.000944	CcSEcCtD
Rasagiline—Nausea—Imiquimod—skin cancer	0.00018	0.000942	CcSEcCtD
Rasagiline—Epistaxis—Docetaxel—skin cancer	0.000179	0.000934	CcSEcCtD
Rasagiline—Nervous system disorder—Temozolomide—skin cancer	0.000178	0.000932	CcSEcCtD
Rasagiline—Convulsion—Fluorouracil—skin cancer	0.000178	0.000929	CcSEcCtD
Rasagiline—Feeling abnormal—Bleomycin—skin cancer	0.000177	0.000928	CcSEcCtD
Rasagiline—Skin disorder—Temozolomide—skin cancer	0.000176	0.000923	CcSEcCtD
Rasagiline—Hyperhidrosis—Temozolomide—skin cancer	0.000175	0.000918	CcSEcCtD
Rasagiline—Chest pain—Fluorouracil—skin cancer	0.000174	0.000913	CcSEcCtD
Rasagiline—Decreased appetite—Dactinomycin—skin cancer	0.000174	0.000913	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—skin cancer	0.000174	0.00414	CbGpPWpGaD
Rasagiline—Anorexia—Temozolomide—skin cancer	0.000173	0.000905	CcSEcCtD
Rasagiline—Discomfort—Fluorouracil—skin cancer	0.000172	0.000902	CcSEcCtD
Rasagiline—Urticaria—Bleomycin—skin cancer	0.000171	0.000895	CcSEcCtD
Rasagiline—Haemoglobin—Docetaxel—skin cancer	0.000171	0.000894	CcSEcCtD
Rasagiline—Rhinitis—Docetaxel—skin cancer	0.00017	0.000891	CcSEcCtD
Rasagiline—Body temperature increased—Bleomycin—skin cancer	0.00017	0.00089	CcSEcCtD
Rasagiline—Haemorrhage—Docetaxel—skin cancer	0.00017	0.000889	CcSEcCtD
Rasagiline—Hypoaesthesia—Docetaxel—skin cancer	0.000169	0.000885	CcSEcCtD
Rasagiline—Confusional state—Fluorouracil—skin cancer	0.000169	0.000882	CcSEcCtD
Rasagiline—Urinary tract disorder—Docetaxel—skin cancer	0.000168	0.000878	CcSEcCtD
Rasagiline—Oedema peripheral—Docetaxel—skin cancer	0.000167	0.000876	CcSEcCtD
Rasagiline—Connective tissue disorder—Docetaxel—skin cancer	0.000167	0.000874	CcSEcCtD
Rasagiline—Urethral disorder—Docetaxel—skin cancer	0.000167	0.000872	CcSEcCtD
Rasagiline—Infection—Fluorouracil—skin cancer	0.000166	0.000869	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—skin cancer	0.000166	0.00396	CbGpPWpGaD
Rasagiline—Feeling abnormal—Dactinomycin—skin cancer	0.000165	0.000865	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000165	0.000865	CcSEcCtD
Rasagiline—BCL2—Immune System—TLR7—skin cancer	0.000165	0.00394	CbGpPWpGaD
Rasagiline—Insomnia—Temozolomide—skin cancer	0.000164	0.000859	CcSEcCtD
Rasagiline—Gastrointestinal pain—Dactinomycin—skin cancer	0.000164	0.000859	CcSEcCtD
Rasagiline—Nervous system disorder—Fluorouracil—skin cancer	0.000164	0.000858	CcSEcCtD
Rasagiline—Paraesthesia—Temozolomide—skin cancer	0.000163	0.000853	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—skin cancer	0.000163	0.00388	CbGpPWpGaD
Rasagiline—Dyspnoea—Temozolomide—skin cancer	0.000162	0.000847	CcSEcCtD
Rasagiline—Somnolence—Temozolomide—skin cancer	0.000161	0.000844	CcSEcCtD
Rasagiline—Dyspepsia—Temozolomide—skin cancer	0.00016	0.000836	CcSEcCtD
Rasagiline—Anorexia—Fluorouracil—skin cancer	0.000159	0.000834	CcSEcCtD
Rasagiline—Eye disorder—Docetaxel—skin cancer	0.000159	0.000831	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—skin cancer	0.000159	0.00378	CbGpPWpGaD
Rasagiline—Abdominal pain—Dactinomycin—skin cancer	0.000159	0.00083	CcSEcCtD
Rasagiline—Body temperature increased—Dactinomycin—skin cancer	0.000159	0.00083	CcSEcCtD
Rasagiline—Hypersensitivity—Bleomycin—skin cancer	0.000159	0.00083	CcSEcCtD
Rasagiline—Decreased appetite—Temozolomide—skin cancer	0.000158	0.000826	CcSEcCtD
Rasagiline—Cardiac disorder—Docetaxel—skin cancer	0.000158	0.000825	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Temozolomide—skin cancer	0.000157	0.00082	CcSEcCtD
Rasagiline—Hypotension—Fluorouracil—skin cancer	0.000156	0.000818	CcSEcCtD
Rasagiline—Constipation—Temozolomide—skin cancer	0.000155	0.000812	CcSEcCtD
Rasagiline—Asthenia—Bleomycin—skin cancer	0.000154	0.000808	CcSEcCtD
Rasagiline—Angiopathy—Docetaxel—skin cancer	0.000154	0.000807	CcSEcCtD
Rasagiline—Immune system disorder—Docetaxel—skin cancer	0.000153	0.000803	CcSEcCtD
Rasagiline—Mediastinal disorder—Docetaxel—skin cancer	0.000153	0.000801	CcSEcCtD
Rasagiline—Chills—Docetaxel—skin cancer	0.000152	0.000798	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000152	0.000797	CcSEcCtD
Rasagiline—Pruritus—Bleomycin—skin cancer	0.000152	0.000797	CcSEcCtD
Rasagiline—MAOB—Metabolism—PLIN2—skin cancer	0.000152	0.00362	CbGpPWpGaD
Rasagiline—Insomnia—Fluorouracil—skin cancer	0.000151	0.000792	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000151	0.00361	CbGpPWpGaD
Rasagiline—Paraesthesia—Fluorouracil—skin cancer	0.00015	0.000786	CcSEcCtD
Rasagiline—Alopecia—Docetaxel—skin cancer	0.00015	0.000786	CcSEcCtD
Rasagiline—Feeling abnormal—Temozolomide—skin cancer	0.00015	0.000783	CcSEcCtD
Rasagiline—Dyspnoea—Fluorouracil—skin cancer	0.000149	0.00078	CcSEcCtD
Rasagiline—Mental disorder—Docetaxel—skin cancer	0.000149	0.000779	CcSEcCtD
Rasagiline—Somnolence—Fluorouracil—skin cancer	0.000149	0.000778	CcSEcCtD
Rasagiline—Gastrointestinal pain—Temozolomide—skin cancer	0.000148	0.000777	CcSEcCtD
Rasagiline—Malnutrition—Docetaxel—skin cancer	0.000148	0.000774	CcSEcCtD
Rasagiline—Hypersensitivity—Dactinomycin—skin cancer	0.000148	0.000774	CcSEcCtD
Rasagiline—Dyspepsia—Fluorouracil—skin cancer	0.000147	0.00077	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FOXO4—skin cancer	0.000146	0.00349	CbGpPWpGaD
Rasagiline—Decreased appetite—Fluorouracil—skin cancer	0.000145	0.000761	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—skin cancer	0.000145	0.00346	CbGpPWpGaD
Rasagiline—Dysgeusia—Docetaxel—skin cancer	0.000145	0.000758	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000144	0.000756	CcSEcCtD
Rasagiline—Urticaria—Temozolomide—skin cancer	0.000144	0.000755	CcSEcCtD
Rasagiline—Asthenia—Dactinomycin—skin cancer	0.000144	0.000753	CcSEcCtD
Rasagiline—Abdominal pain—Temozolomide—skin cancer	0.000144	0.000751	CcSEcCtD
Rasagiline—Body temperature increased—Temozolomide—skin cancer	0.000144	0.000751	CcSEcCtD
Rasagiline—Back pain—Docetaxel—skin cancer	0.000143	0.000749	CcSEcCtD
Rasagiline—Muscle spasms—Docetaxel—skin cancer	0.000142	0.000744	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—skin cancer	0.000141	0.00336	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—skin cancer	0.000139	0.00331	CbGpPWpGaD
Rasagiline—Feeling abnormal—Fluorouracil—skin cancer	0.000138	0.000721	CcSEcCtD
Rasagiline—Diarrhoea—Dactinomycin—skin cancer	0.000137	0.000719	CcSEcCtD
Rasagiline—Vomiting—Bleomycin—skin cancer	0.000137	0.000716	CcSEcCtD
Rasagiline—Anaemia—Docetaxel—skin cancer	0.000137	0.000715	CcSEcCtD
Rasagiline—Rash—Bleomycin—skin cancer	0.000136	0.00071	CcSEcCtD
Rasagiline—Dermatitis—Bleomycin—skin cancer	0.000136	0.000709	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—skin cancer	0.000135	0.00322	CbGpPWpGaD
Rasagiline—Hypersensitivity—Temozolomide—skin cancer	0.000134	0.0007	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—skin cancer	0.000133	0.00317	CbGpPWpGaD
Rasagiline—Urticaria—Fluorouracil—skin cancer	0.000133	0.000695	CcSEcCtD
Rasagiline—Syncope—Docetaxel—skin cancer	0.000133	0.000694	CcSEcCtD
Rasagiline—Leukopenia—Docetaxel—skin cancer	0.000132	0.000693	CcSEcCtD
Rasagiline—Body temperature increased—Fluorouracil—skin cancer	0.000132	0.000692	CcSEcCtD
Rasagiline—Asthenia—Temozolomide—skin cancer	0.00013	0.000682	CcSEcCtD
Rasagiline—Loss of consciousness—Docetaxel—skin cancer	0.00013	0.00068	CcSEcCtD
Rasagiline—Cough—Docetaxel—skin cancer	0.000129	0.000675	CcSEcCtD
Rasagiline—Pruritus—Temozolomide—skin cancer	0.000128	0.000672	CcSEcCtD
Rasagiline—Convulsion—Docetaxel—skin cancer	0.000128	0.000671	CcSEcCtD
Rasagiline—Nausea—Bleomycin—skin cancer	0.000128	0.000669	CcSEcCtD
Rasagiline—Hypertension—Docetaxel—skin cancer	0.000128	0.000668	CcSEcCtD
Rasagiline—Vomiting—Dactinomycin—skin cancer	0.000128	0.000668	CcSEcCtD
Rasagiline—Rash—Dactinomycin—skin cancer	0.000127	0.000662	CcSEcCtD
Rasagiline—Arthralgia—Docetaxel—skin cancer	0.000126	0.000659	CcSEcCtD
Rasagiline—Chest pain—Docetaxel—skin cancer	0.000126	0.000659	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000125	0.000654	CcSEcCtD
Rasagiline—Diarrhoea—Temozolomide—skin cancer	0.000124	0.00065	CcSEcCtD
Rasagiline—Hypersensitivity—Fluorouracil—skin cancer	0.000123	0.000645	CcSEcCtD
Rasagiline—Dry mouth—Docetaxel—skin cancer	0.000123	0.000644	CcSEcCtD
Rasagiline—MAOB—Metabolism—CSPG4—skin cancer	0.000122	0.00292	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000122	0.00291	CbGpPWpGaD
Rasagiline—Confusional state—Docetaxel—skin cancer	0.000122	0.000637	CcSEcCtD
Rasagiline—Dizziness—Temozolomide—skin cancer	0.00012	0.000628	CcSEcCtD
Rasagiline—Infection—Docetaxel—skin cancer	0.00012	0.000628	CcSEcCtD
Rasagiline—Nausea—Dactinomycin—skin cancer	0.000119	0.000624	CcSEcCtD
Rasagiline—Shock—Docetaxel—skin cancer	0.000119	0.000621	CcSEcCtD
Rasagiline—Nervous system disorder—Docetaxel—skin cancer	0.000118	0.000619	CcSEcCtD
Rasagiline—Pruritus—Fluorouracil—skin cancer	0.000118	0.000619	CcSEcCtD
Rasagiline—Skin disorder—Docetaxel—skin cancer	0.000117	0.000614	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—skin cancer	0.000115	0.00275	CbGpPWpGaD
Rasagiline—Vomiting—Temozolomide—skin cancer	0.000115	0.000604	CcSEcCtD
Rasagiline—Anorexia—Docetaxel—skin cancer	0.000115	0.000602	CcSEcCtD
Rasagiline—Rash—Temozolomide—skin cancer	0.000114	0.000599	CcSEcCtD
Rasagiline—Diarrhoea—Fluorouracil—skin cancer	0.000114	0.000599	CcSEcCtD
Rasagiline—Dermatitis—Temozolomide—skin cancer	0.000114	0.000598	CcSEcCtD
Rasagiline—Headache—Temozolomide—skin cancer	0.000114	0.000595	CcSEcCtD
Rasagiline—Hypotension—Docetaxel—skin cancer	0.000113	0.00059	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000113	0.00268	CbGpPWpGaD
Rasagiline—Dizziness—Fluorouracil—skin cancer	0.000111	0.000579	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00011	0.000576	CcSEcCtD
Rasagiline—Insomnia—Docetaxel—skin cancer	0.000109	0.000571	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000109	0.00259	CbGpPWpGaD
Rasagiline—Paraesthesia—Docetaxel—skin cancer	0.000108	0.000567	CcSEcCtD
Rasagiline—Nausea—Temozolomide—skin cancer	0.000108	0.000564	CcSEcCtD
Rasagiline—Dyspnoea—Docetaxel—skin cancer	0.000108	0.000563	CcSEcCtD
Rasagiline—Somnolence—Docetaxel—skin cancer	0.000107	0.000562	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—skin cancer	0.000106	0.00254	CbGpPWpGaD
Rasagiline—Vomiting—Fluorouracil—skin cancer	0.000106	0.000556	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—skin cancer	0.000106	0.000556	CcSEcCtD
Rasagiline—Rash—Fluorouracil—skin cancer	0.000105	0.000552	CcSEcCtD
Rasagiline—Dermatitis—Fluorouracil—skin cancer	0.000105	0.000551	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	0.000105	0.00251	CbGpPWpGaD
Rasagiline—Decreased appetite—Docetaxel—skin cancer	0.000105	0.000549	CcSEcCtD
Rasagiline—Headache—Fluorouracil—skin cancer	0.000105	0.000548	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—skin cancer	0.000104	0.000545	CcSEcCtD
Rasagiline—Constipation—Docetaxel—skin cancer	0.000103	0.00054	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000101	0.00241	CbGpPWpGaD
Rasagiline—Feeling abnormal—Docetaxel—skin cancer	9.95e-05	0.000521	CcSEcCtD
Rasagiline—Nausea—Fluorouracil—skin cancer	9.93e-05	0.00052	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—skin cancer	9.87e-05	0.000517	CcSEcCtD
Rasagiline—Abdominal pain—Docetaxel—skin cancer	9.54e-05	0.000499	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—skin cancer	9.54e-05	0.000499	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	9e-05	0.00215	CbGpPWpGaD
Rasagiline—Hypersensitivity—Docetaxel—skin cancer	8.89e-05	0.000465	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	8.76e-05	0.00209	CbGpPWpGaD
Rasagiline—Asthenia—Docetaxel—skin cancer	8.66e-05	0.000453	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—skin cancer	8.65e-05	0.00206	CbGpPWpGaD
Rasagiline—Pruritus—Docetaxel—skin cancer	8.54e-05	0.000447	CcSEcCtD
Rasagiline—BCL2—Immune System—FOXO4—skin cancer	8.52e-05	0.00203	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ENO2—skin cancer	8.31e-05	0.00198	CbGpPWpGaD
Rasagiline—Diarrhoea—Docetaxel—skin cancer	8.26e-05	0.000432	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—skin cancer	7.98e-05	0.000418	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.89e-05	0.00188	CbGpPWpGaD
Rasagiline—Vomiting—Docetaxel—skin cancer	7.68e-05	0.000402	CcSEcCtD
Rasagiline—Rash—Docetaxel—skin cancer	7.61e-05	0.000398	CcSEcCtD
Rasagiline—Dermatitis—Docetaxel—skin cancer	7.6e-05	0.000398	CcSEcCtD
Rasagiline—Headache—Docetaxel—skin cancer	7.56e-05	0.000396	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	7.54e-05	0.0018	CbGpPWpGaD
Rasagiline—Nausea—Docetaxel—skin cancer	7.17e-05	0.000375	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	6.41e-05	0.00153	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NRAS—skin cancer	4.86e-05	0.00116	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ERCC2—skin cancer	4.83e-05	0.00115	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—skin cancer	4.18e-05	0.000997	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—skin cancer	3.56e-05	0.000848	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLIN2—skin cancer	3.51e-05	0.000837	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—skin cancer	3.4e-05	0.000811	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—skin cancer	2.9e-05	0.00069	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—skin cancer	2.83e-05	0.000675	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CSPG4—skin cancer	2.83e-05	0.000675	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—skin cancer	2.44e-05	0.000581	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—skin cancer	2.07e-05	0.000494	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—skin cancer	1.98e-05	0.000473	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO2—skin cancer	1.92e-05	0.000459	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.5e-05	0.000359	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ERCC2—skin cancer	1.12e-05	0.000266	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—skin cancer	6.7e-06	0.00016	CbGpPWpGaD
